Kinnate Biopharma Inc expected to post a loss of 61 cents a share - Earnings Preview

Kinnate Biopharma

05/11/2022 03:02

* Kinnate Biopharma Inc  KNTE.OQ   KNTE.O  is expected
to show no
change in quarterly revenue when it reports  results on November
8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Kinnate Biopharma
Inc is
for a loss of 61 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $33​, above​ its last closing price of $8.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.66       -0.64      -0.62     Beat    2.9
 Mar. 31 2022  -0.62       -0.61      -0.61     Met     -0.5
 Dec. 31 2021  -0.60       -0.59      -0.60     Missed  -2.2​
 Sep. 30 2021  -0.55       -0.54      -0.57     Missed  -5.6
 ​​Jun.        -0.44       -0.43      -0.49     Missed  -14
 30 2021                                                
 Mar. 31 2021  -0.36       -0.36      -0.40     Missed  -10.3​
 Dec. 31 2020  -0.37       -0.37      -0.32     Beat    14.1
 This summary was machine generated November 5 at 03:01 GMT.  All
figures in US dollars  unless otherwise stated